ストックスクリーナーアプリを入手
13.37
1.55%
-0.21
プレマーケット:
13.34
-0.03
-0.22%
前日終値:
$13.58
開ける：
$13.46
24時間の取引高:
631.22K
Relative Volume:
1.17
時価総額：
$1.71B
収益：
-
当期純損益:
-
株価収益率:
-6.203
EPS:
-2.1554
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+1.36%
1か月 パフォーマンス:
-16.44%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$13.01
$13.46
1週間の範囲:
$12.17
$14.00
52週間の値動き範囲:
$11.00
$16.75
Generate Biomedicines Inc Stock (GENB) Company Profile
名前
Generate Biomedicines Inc
セクター
電話
888-469-0055
住所
101 SOUTH STREET, SUITE 900, SOMERVILLE
Compare GENB vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GENB
Generate Biomedicines Inc
|
13.37 | 1.74B | 0 | 0 | 0 | -2.1554 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Generate Biomedicines Inc Stock (GENB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-13 | 開始されました | H.C. Wainwright | Buy |
| 2026-03-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2026-03-24 | 開始されました | Goldman | Buy |
| 2026-03-24 | 開始されました | Guggenheim | Buy |
| 2026-03-24 | 開始されました | Morgan Stanley | Overweight |
| 2026-03-24 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Generate Biomedicines Inc (GENB) 最新ニュース
Generate Biomedicines Surges 9.69%: Breaking Resistance Levels in Biotech RallyIntraday Trade Ideas - newsline.com
Top Generate Biomedicines (GENB) Competitors 2026 - MarketBeat
Generate Biomedicines Inc. (GENB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Generate Biomedicines, Inc. (GENB) Market Cap - Zacks Investment Research
GENB Price Today: Generate Biomedicines, Inc. Stock Price, Quote & Chart | MEXC - MEXC
Why Is Generate Biomedicines, Inc. (GENB) Stock Down Today? - Meyka
Generate Biomedicines (GENB) Tumbles 7% as Selling Pressure Mounts – Key Support Levels in FocusSentiment Shift - newsline.com
Why Is Generate Biomedicines, Inc. (GENB) Stock Up Today? - Meyka
A Look At Generate Biomedicines (GENB) Valuation As Shares Soften After Recent Gains - Yahoo Finance
Assessing Generate Biomedicines (GENB) Valuation As Losses Mount And Price To Book Sits At 3.3x - simplywall.st
A New $21 Million Position Signals Confidence in This Post-IPO Drug Developer - The Globe and Mail
symbol__ Stock Quote Price and Forecast - CNN
Generate Biomedicines Inc. (GENB) Q1 2026 Earnings: Wider-than-Expected Loss Underscores Pre-Revenue Development StageEarnings Analysis - newsline.com
Generate Biomedicines to Participate in Goldman Sachs Healthcare Conference on May 28, 2026 - geneonline.com
Generate Biomedicines (GENB) Stock News - Stock Titan
Generate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference - Yahoo Finance
IPO Tracker 2026: Kardigan cozies up to public markets to support heart disease drugs - BioSpace
This AI biotech stock landed a $10.4 million Nvidia investment - MSN
Can Nvidia’s Backing Reframe Generate Biomedicines (GENB) as a Scaled AI Drug Developer? - simplywall.st
A Look At Generate Biomedicines (GENB) Valuation After Nvidia’s US$10.4 Million Investment - simplywall.st
This AI Biotech Stock Landed a $10.4 Million Nvidia Investment - Yahoo Finance
A Deep Dive Into Nvidia’s Latest Portfolio Moves - Investing.com
Generate Biomedicines (GENB) News Flow - Moomoo
Generate Biomedicines, Inc.Common Stock (Nasdaq:GENB) Stock Quote - The Chronicle-Journal
Generate Biomedicines (GENB) Q1 2026 Miss: What Went WrongPretax Income Report - The Legal Advocate
Trades UpdateBuying More Generate BiomedicinesDeepDive - Moomoo
AI Protein Design Market 2026-2033 | Market Growth to FY (Q2) - openPR.com
Flagship entities disclose large GENB holdings, Flagship Pioneering holds 48.9% (GENB) - Stock Titan
Generate Biomedicines (NASDAQ: GENB) exec Michael Nally holds 5.2% stake - Stock Titan
Generate Biomedicines (GENB) Q1 2026 Disappoints — EPS $-1.06 Below $-0.51 ViewsGAAP Earnings Report - newsline.com
GENB : Generate Biomedicines, Inc. Key Company Metrics & Non-finance Metrics - Zacks Investment Research
GENB: Generate Biomedicines, Inc.Brokerage Recommendations Chart - Zacks Investment Research
Morgan Stanley Maintains Generate Biomedicines(GENB.US) With Buy Rating, Raises Target Price to $22 - Moomoo
Programmable Biology: Will GENB Generate Investor Interest? - RTTNews
Generate Biomedicines (GENB) price target increased by 10.47% to 24.22 - MSN
Generate Biomedicines, Inc. Stock 12‑Month Price Target Raised to $25.4, Implies 57% Upside - TradingView
Generate Biomedicines, Inc. (GENB) Ps Ratio (TTM) - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Enterprise Value - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Free Cash Flow (TTM) - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Revenue (Quarterly) - Zacks Investment Research
Dividend HistoryGenerate Biomedicines, Inc. (GENB) - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Book Value - Zacks Investment Research
Generate Biomedicines Inc (GENB) 財務データ
収益
当期純利益
現金流量
EPS
Generate Biomedicines Inc (GENB) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Grous Beth | Chief People Officer |
Mar 02 '26 |
Buy |
16.00 |
300 |
4,800 |
300 |
| Silvers Jason | President & CFO |
Mar 02 '26 |
Buy |
16.00 |
2,000 |
32,000 |
1,000 |
| AFEYAN NOUBAR | Director |
Mar 02 '26 |
Buy |
16.00 |
4,687,500 |
75,000,000 |
15,264,724 |
| Mendillo Jane L | Director |
Mar 02 '26 |
Buy |
16.00 |
1,500 |
24,000 |
1,500 |
| AFEYAN NOUBAR | Director |
Mar 02 '26 |
Buy |
16.00 |
4,687,500 |
75,000,000 |
15,264,724 |
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):